Stay updated on Dolatav Clinical Trial: Nucleoside Sparing in HIV-1
Sign up to get notified when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.

Latest updates to the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page
- Check4 days agoChange DetectedRevision: v3.3.4 is now displayed and Revision: v3.3.3 has been removed. This appears to be a minor version label update rather than substantive content.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedFooter now displays 'Revision: v3.3.3'. The HHS Vulnerability Disclosure link and the previous 'Revision: v3.3.2' entry were removed.SummaryDifference0.1%

- Check54 days agoChange DetectedThe Publications section now includes a note stating that publications are provided voluntarily by the person entering information and pertain to the study results. The revision tag was updated to v3.3.2, replacing v3.2.0.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page no longer displays the government funding status notice related to NIH operations; the core study details and sections remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check76 days agoChange DetectedThe new screenshot shows only layout and styling adjustments with no changes to the study's title, objectives, eligibility criteria, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check104 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%

Stay in the know with updates to Dolatav Clinical Trial: Nucleoside Sparing in HIV-1
Enter your email address, and we'll notify you when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.